Results 31 to 40 of about 2,650 (185)
Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration [PDF]
, 2021 PURPOSE: Although intraocular anti-vascular endothelial growth factors (anti-VEGFs) are effective as treatment of neovascular age-related macular degeneration (nAMD), the (economic) burden on the healthcare system is considerable. A treat-and-extend (T&E)
de Jong, L. A. +5 more
core +1 more source
BMC Ophthalmology, 2022 Background We present a case of retinal occlusive vasculitis following brolucizumab administration and the first report of optical coherence tomography angiography (OCTA) findings after treatment.
Eun Kyoung Lee +3 more
doaj +1 more source
Antiangiogenic Drugs in the Treatment of Diabetic Macular Edema [PDF]
, 2023 The article presents the characteristics of the first antiangiogenic drug registered for the treatment of diabetic macular edema, ranibizumab, as well as the new long-acting drug ...
Mavlonov N. X.
core +2 more sources
Scientific Reports, 2023 We previously reported one-year results of a treat-and-extend (TAE) regimen with intravitreal brolucizumab for 68 eyes with treatment-naïve neovascular age-related macular degeneration (nAMD) associated with type 1 macular neovascularization (MNV).
Hidetaka Matsumoto +3 more
doaj +1 more source
American Journal of Ophthalmology Case Reports, 2021 Purpose: To report the efficacy of intravitreal injection (IVI) of brolucizumab for recalcitrant diabetic macular edema (DME) in a real-world setting. Observations: This was a single-center, prospective uncontrolled non-randomized case series. Three eyes
Debdulal Chakraborty +3 more
doaj +1 more source
American Journal of Ophthalmology Case Reports, 2022 Purpose: To describe the efficacy and safety of brolucizumab (Beovu®, Novartis Pharmaceuticals) in a case of cystoid macular edema associated with radiation retinopathy as a result of iodine-125 plaque brachytherapy (PBT) for choroidal melanoma ...
Natacha C. Villegas +5 more
doaj +1 more source
Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose [PDF]
, 2023 Background: The effects of various dosages and treatment regimens on intravitreal aflibercept concentrations and the proportion of free vascular endothelial growth factor (VEGF) to total VEGF were evaluated using a drug and disease assessment model.
Di Bin, Francesco +3 more
core +1 more source
Brolucizumab for Neovascular Age-Related Macular Degeneration in Real-World Setting
IJRETINA (International Journal of Retina), 2023 Introduction: The mainstay treatment for neovascular AMD (nAMD) is intravitreal injections of anti-vascular growth factor (anti-VEGF) agents. Based on clinical trials, a newly developed anti-VEGF named brolucizumab showed noninferiority in anatomical and
Andi Marsa Nadhira +2 more
doaj +1 more source
Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration [PDF]
, 2022 In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the ...
core +1 more source
The Role of Inflammation in Age-Related Macular Degeneration: Updates and Possible Therapeutic Approaches [PDF]
, 2022 Age-related macular degeneration (AMD) is a common retinal disease characterized by complex pathogenesis and extremely heterogeneous characteristics.
Aragona, Emanuela +2 more
core +1 more source